← All trials
NCT05301010
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2018
- Primary completion
- Feb 19, 2021
- Completion date
- Feb 19, 2021
- First posted
- Mar 29, 2022
- Last posted
- Mar 29, 2022
- Enrollment
- 128
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Epoch BiosciencesLead sponsor
- Vietstar Biomedical ResearchCollaborator
- MedProve IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.